Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance
- PMID: 17177309
- DOI: 10.1002/jmv.20767
Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance
Abstract
Lentiviruses are unique in their ability to infect both dividing and non-dividing cells. This makes the vectors derived from them particularly useful for gene transfer into non-dividing cells, including stem cells. Lentiviral vectors are becoming the vectors of choice for si/shRNA delivery. The utility of the lentiviral vectors will be enhanced if additional elements of safety are built into their design. One safety concern is the generation of replication competent virus by recombination. We reasoned that HIV-1 and HIV-2 hybrid or chimeric lentiviral vectors will have added safety insurance in this regard. This is based on the premise that HIV-1 and HIV-2 are dissimilar enough in sequence to curtail recombination, yet similar enough to complement functionally. For hybrid vectors, we found that both HIV-1 and HIV-2 transfer vector RNAs could be packaged to equivalent titer by the HIV-1 packaging machinery. However, HIV-2 packaging machinery was unable to package HIV-1 transfer vector as well as it did HIV-2 transfer vector. This non-reciprocacity suggested that the requirement for HIV-2 vectors was more stringent and that for HIV-1 vectors more promiscuous. When the HIV-1 transfer vector was packaged with the chimeric packaging construct where the leader-gag region of HIV-2 was replaced with that of HIV-1 packaging construct, the titer of the vector went up. This suggests that at least some of the determinants of specificity for vector assembly reside in the leader-gag region. Incorporation of central polypurine tract (cPPT) and woodchuck post-transcriptional enhance element (WPRE) into the HIV-2 vectors had only modest effect on vector titer. Thus, chimeric lentiviral vectors with added safety features can be designed without compromising transduction efficiency.
Similar articles
-
Identification of unique reciprocal and non reciprocal cross packaging relationships between HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral vector system with highly favourable features for in vivo testing and clinical usage.Retrovirology. 2005 Sep 16;2:55. doi: 10.1186/1742-4690-2-55. Retrovirology. 2005. PMID: 16168051 Free PMC article.
-
Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.Hum Gene Ther. 2000 Nov 20;11(17):2403-13. doi: 10.1089/104303400750038507. Hum Gene Ther. 2000. PMID: 11096444
-
Production of lentiviral vectors for transducing cells from the central nervous system.J Vis Exp. 2012 May 24;(63):e4031. doi: 10.3791/4031. J Vis Exp. 2012. PMID: 22664962 Free PMC article.
-
Safety considerations in vector development.Somat Cell Mol Genet. 2001 Nov;26(1-6):147-58. doi: 10.1023/a:1021082815013. Somat Cell Mol Genet. 2001. PMID: 12465466 Review.
-
HIV RNA packaging and lentivirus-based vectors.Adv Pharmacol. 2000;48:1-28. doi: 10.1016/s1054-3589(00)48002-6. Adv Pharmacol. 2000. PMID: 10987087 Review.
Cited by
-
Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.Hum Gene Ther. 2015 Oct;26(10):680-7. doi: 10.1089/hum.2015.031. Epub 2015 Aug 6. Hum Gene Ther. 2015. PMID: 26077977 Free PMC article.
-
Generation of Islet-like Cell Aggregates from Human Adipose Tissue-derived Stem Cells by Lentiviral Overexpression of PDX-1.Int J Organ Transplant Med. 2015;6(2):61-76. Int J Organ Transplant Med. 2015. PMID: 26082830 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical